Optimal Management of Relapsing Multiple Sclerosis

Fred D. Lublin, MD discusses the diagnosis of multiple sclerosis and the 2017 revisions of the McDonald criteria.  

Experts in multiple sclerosis (MS) provide an overview of treatment strategies and selection in relapsing MS.

Fred D. Lublin, MD, Ravi Dukkipati, MD, and Lauren Gluck, MD, discuss interferons and glatiramer as platform therapies in multiple sclerosis.

Gavin Giovannoni, MD provides an overview of the development and pharmacodynamics of cladribine in multiple sclerosis.

Key opinion leaders provide insight into the use cladribine for relapsing multiple sclerosis including durability and safety profile.

Expert neurologists discuss the role of sphingosine-1-phosphate (S1P) receptor modulators in relapsing multiple sclerosis including vaccine considerations and pediatric use.

A panel of experts discuss the use of anti-CD20 monoclonal antibodies in relapsing multiple sclerosis including summaries of the phase III ORATORIO and ASCLEPIOS trials, for ocrelizumab and ofatumumab, respectively.

Experts in the field of multiple sclerosis provide insight into the fumarates as a viable oral option for relapsing MS.  

Lauren Gluck, MD, and Ravi Dukkipati, MD, provide an overview of teriflunomide for relapsing multiple sclerosis including its safety and tolerability profile.

Lauren Gluck, MD discusses considerations for monitoring response to treatment in relapsing multiple sclerosis.

Experts in multiple sclerosis (MS) discuss key factors involved in the sequencing of therapies for relapsing MS.

A panel of experts emphasize the importance of shared decision making in relapsing multiple sclerosis and discuss lifestyle choices that impact the disease.

Expert neurologists discuss current and future biomarkers relevant to relapsing multiple sclerosis including cerebrospinal fluid neurofilament.

Key opinion leaders in multiple sclerosis (MS) discuss the future of relapsing MS management and unmet needs.